{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:59:44Z","timestamp":1790085584078,"version":"4.0.1"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RR220088"],"award-info":[{"award-number":["RR220088"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.biopha.2026.119912","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T22:40:15Z","timestamp":1788561615000},"page":"119912","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Restoration of tumor vascular integrity by P188 improves chemotherapy and immunotherapy efficacy in triple negative breast cancer"],"prefix":"10.1016","volume":"203","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8470-7437","authenticated-orcid":false,"given":"Anne M.","family":"Alsup","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9354-6556","authenticated-orcid":false,"given":"Mina","family":"Maksimos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5985-3456","authenticated-orcid":false,"given":"Eman","family":"Fayyaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8612-3414","authenticated-orcid":false,"given":"Yoksha","family":"Muruganantham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8837-864X","authenticated-orcid":false,"given":"Mia","family":"Grubbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6647-9745","authenticated-orcid":false,"given":"Malak","family":"Al-Noubani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeideh","family":"Arsalani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tithi","family":"Bhattacharyya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Cheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Obed","family":"Asare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feda","family":"Azab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tran N.H.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangeetha M.","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6371-2780","authenticated-orcid":false,"given":"Abdel Kareem","family":"Azab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.biopha.2026.119912_bib1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA A Cancer Journal Clinicians"},{"issue":"1","key":"10.1016\/j.biopha.2026.119912_bib2","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12935-020-01719-5","article-title":"The role of hypoxia in the tumor microenvironment and development of cancer stem cell: a novel approach to developing treatment","volume":"21","author":"Emami Nejad","year":"2021","journal-title":"Cancer Cell. Int."},{"key":"10.1016\/j.biopha.2026.119912_bib3","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1146\/annurev-physiol-020518-114700","article-title":"Normalizing function of tumor vessels: progress, opportunities, and challenges","volume":"81","author":"Martin","year":"2019","journal-title":"Annu. Rev. Physiol."},{"issue":"12","key":"10.1016\/j.biopha.2026.119912_bib4","doi-asserted-by":"crossref","first-page":"6415","DOI":"10.3390\/ijms25126415","article-title":"Molecular mechanisms regulating vascular endothelial permeability","volume":"25","author":"Wakasugi","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"7070","key":"10.1016\/j.biopha.2026.119912_bib5","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/nature04478","article-title":"Angiogenesis in life, disease and medicine","volume":"438","author":"Carmeliet","year":"2005","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.biopha.2026.119912_bib6","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1177\/1947601911423654","article-title":"Hypoxia-induced angiogenesis: good and evil","volume":"2","author":"Krock","year":"2011","journal-title":"Genes. Cancer"},{"key":"10.1016\/j.biopha.2026.119912_bib7","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2147\/HP.S93413","article-title":"The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy","volume":"3","author":"Muz","year":"2015","journal-title":"Hypoxia"},{"issue":"13","key":"10.1016\/j.biopha.2026.119912_bib8","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1158\/1078-0432.CCR-13-0462","article-title":"Cell Trafficking of Endothelial Progenitor Cells in Tumor Progression","volume":"19","author":"de la Puente","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.biopha.2026.119912_bib9","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.tips.2019.07.001","article-title":"Tumor Vasculatures: A New Target for Cancer Immunotherapy","volume":"40","author":"Liu","year":"2019","journal-title":"Trends Pharmacol. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2026.119912_bib10","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.gde.2010.10.008","article-title":"Vessel abnormalization: another hallmark of cancer?: Molecular mechanisms and therapeutic implications","volume":"21","author":"De Bock","year":"2011","journal-title":"Curr. Opin. Genet. & Dev."},{"issue":"10","key":"10.1016\/j.biopha.2026.119912_bib11","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/s41568-024-00736-0","article-title":"Targeting the tumour vasculature: from vessel destruction to promotion","volume":"24","author":"Guelfi","year":"2024","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2026.119912_bib12","doi-asserted-by":"crossref","first-page":"R35","DOI":"10.1530\/VB-19-0032","article-title":"Tumour vessel remodelling: new opportunities in cancer treatment","volume":"2","author":"Ganss","year":"2020","journal-title":"Vasc. Biol."},{"issue":"7","key":"10.1016\/j.biopha.2026.119912_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15071990","article-title":"Anti-Angiogenic Activity of Drugs in Multiple Myeloma","volume":"15","author":"Saltarella","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.biopha.2026.119912_bib14","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0360-3016(96)00628-1","article-title":"An antiangiogenic agent (TNP-470) inhibited reoxygenation during fractionated radiotherapy of murine mammary carcinoma","volume":"37","author":"Murata","year":"1997","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.biopha.2026.119912_bib15","article-title":"Reassessing vascular endothelial growth factor (VEGF) in anti-angiogenic cancer therapy","volume":"32","author":"Elebiyo","year":"2022","journal-title":"Cancer Treat. Res. Commun."},{"issue":"6","key":"10.1016\/j.biopha.2026.119912_bib16","first-page":"553","article-title":"Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases","volume":"6","author":"Winkler","year":"2004","journal-title":"Cancer Cell."},{"issue":"21","key":"10.1016\/j.biopha.2026.119912_bib17","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor Angiogenesis: Therapeutic Implications","volume":"285","author":"Folkman","year":"1971","journal-title":"New. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.biopha.2026.119912_bib18","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s10238-025-01857-y","article-title":"The discovery of Bevacizumab. An historical reappraisal","volume":"25","author":"Ribatti","year":"2025","journal-title":"Clin. Exp. Med."},{"issue":"8","key":"10.1016\/j.biopha.2026.119912_bib19","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1634\/theoncologist.2009-0088","article-title":"Sorafenib and sunitinib","volume":"14","author":"Kim","year":"2009","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.biopha.2026.119912_bib20","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.pharmthera.2013.09.003","article-title":"Bevacizumab and micrometastases: Revisiting the preclinical and clinical rollercoaster","volume":"141","author":"Mountzios","year":"2014","journal-title":"Pharmacol. & Ther."},{"key":"10.1016\/j.biopha.2026.119912_bib21","first-page":"519","article-title":"Anti-angiogenic Therapy in Cancer: Downsides and New Pivots for Precision Medicine","volume":"7","author":"Lupo","year":"2016","journal-title":"Front. Pharmacol."},{"issue":"9863","key":"10.1016\/j.biopha.2026.119912_bib22","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.biopha.2026.119912_bib23","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1200\/JCO.2010.28.1386","article-title":"Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303)","volume":"28","author":"Kindler","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119912_bib24","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1200\/JCO.2012.48.5268","article-title":"Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer","volume":"32","author":"Michaelson","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.biopha.2026.119912_bib25","first-page":"5491","article-title":"Pharmacodynamic-mediated Reduction of Temozolomide Tumor Concentrations by the Angiogenesis Inhibitor TNP-4701","volume":"61","author":"Ma","year":"2001","journal-title":"Cancer Res."},{"issue":"5706","key":"10.1016\/j.biopha.2026.119912_bib26","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1126\/science.1104819","article-title":"Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy","volume":"307","author":"Jain","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.biopha.2026.119912_bib27","doi-asserted-by":"crossref","unstructured":"H. Hurwitz et al., \"Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer,\" New England Journal of Medicine, vol. 350, no. 23, pp. 2335-2342, doi: 10.1056\/NEJMoa032691.","DOI":"10.1056\/NEJMoa032691"},{"key":"10.1016\/j.biopha.2026.119912_bib28","doi-asserted-by":"crossref","unstructured":"F. Loupakis et al., \"Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer,\" New England Journal of Medicine, vol. 371, no. 17, pp. 1609-1618, doi: 10.1056\/NEJMoa1403108.","DOI":"10.1056\/NEJMoa1403108"},{"key":"10.1016\/j.biopha.2026.119912_bib29","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3389\/fonc.2020.00221","article-title":"Resistance Mechanisms to Anti-angiogenic Therapies in Cancer","volume":"10","author":"Haibe","year":"2020","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119912_bib30","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.ajpath.2017.01.010","article-title":"Hypoxia-Mediated Mechanisms Associated with Antiangiogenic Treatment Resistance in Glioblastomas","volume":"187","author":"Mahase","year":"2017","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.biopha.2026.119912_bib31","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3389\/fimmu.2018.00527","article-title":"Contribution to Tumor Angiogenesis From Innate Immune Cells Within the Tumor Microenvironment: Implications for Immunotherapy","volume":"9","author":"Albini","year":"2018","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119912_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0927-7757(94)03028-X","article-title":"Poly(ethylene oxide) poly(propylene oxide) poly(ethylene oxide) block copolymer surfactants in aqueous solutions and at interfaces: thermodynamics, structure, dynamics, and modeling","volume":"96","author":"Alexandridis","year":"1995","journal-title":"Colloids Surf. A Physicochem. Eng. Asp."},{"issue":"3","key":"10.1016\/j.biopha.2026.119912_bib33","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0006-3495(02)75499-4","article-title":"Direct Observation of Poloxamer 188 Insertion into Lipid Monolayers","volume":"82","author":"Maskarinec","year":"2002","journal-title":"Biophys. J."},{"issue":"2","key":"10.1016\/j.biopha.2026.119912_bib34","first-page":"115","article-title":"Poloxamer 188 inhibition of ischemia\/reperfusion injury: evidence for a novel anti-adhesive mechanism","volume":"40","author":"Hunter","year":"2010","journal-title":"Ann. Clin. Lab. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2026.119912_bib35","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1038\/s41598-020-59888-2","article-title":"Modulation of in vitro Brain Endothelium by Mechanical Trauma: Structural and Functional Restoration by Poloxamer 188","volume":"10","author":"Inyang","year":"2020","journal-title":"Sci. Rep."},{"issue":"07","key":"10.1016\/j.biopha.2026.119912_bib36","doi-asserted-by":"crossref","first-page":"301","DOI":"10.4236\/jbise.2025.187022","article-title":"Active Transport of Therapeutic Triblock Amphiphilic Polymer Poloxamer 188 in Brain Endothelial Cells for Cellular Repair","volume":"18","author":"Alatrash","year":"2025","journal-title":"J. Biomed. Sci. Eng."},{"key":"10.1016\/j.biopha.2026.119912_bib37","doi-asserted-by":"crossref","first-page":"100","DOI":"10.4236\/jbise.2026.192009","article-title":"Poloxamer 188 Modulates Cytoskeletal Dynamics and Mitochondrial Reassembly during Endothelial Repair in Vitro","volume":"19","author":"Grubbs","year":"2026","journal-title":"J. Biomed. Sci. Eng."},{"issue":"1","key":"10.1016\/j.biopha.2026.119912_bib38","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s40883-021-00206-1","article-title":"Amphiphilic Block Copolymer-Catalyzed Cell Membrane Sealing Is Linked to Decreased Membrane Tension","volume":"8","author":"Maatouk","year":"2022","journal-title":"Regen. Eng. Transl. Med."},{"issue":"4","key":"10.1016\/j.biopha.2026.119912_bib39","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1007\/s12031-015-0568-8","article-title":"Poloxamer 188 Attenuates Cerebral Hypoxia\/Ischemia Injury in Parallel with Preventing Mitochondrial Membrane Permeabilization and Autophagic Activation","volume":"56","author":"Luo","year":"2015","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.biopha.2026.119912_bib40","unstructured":"H.-J. Bao et al., \"Poloxamer-188 Attenuates TBI-Induced Blood\u2013Brain Barrier Damage Leading to Decreased Brain Edema and Reduced Cellular Death.\""},{"key":"10.1016\/j.biopha.2026.119912_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.650573","article-title":"Poloxamer 188 Attenuates Ischemia-Reperfusion-Induced Lung Injury by Maintaining Cell Membrane Integrity and Inhibiting Multiple Signaling Pathways","volume":"12","author":"Tang","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"17","key":"10.1016\/j.biopha.2026.119912_bib42","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1001\/jama.286.17.2099","article-title":"Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease: A randomized controlled trial","volume":"286","author":"Orringer","year":"2001","journal-title":"Jama"},{"issue":"3","key":"10.1016\/j.biopha.2026.119912_bib43","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/bdd.297","article-title":"Pharmacokinetics of a novel surface-active agent, purified poloxamer 188, in rat, rabbit, dog and man","volume":"23","author":"Grindel","year":"2002","journal-title":"Biopharm. & Drug. Dispos."},{"issue":"5","key":"10.1016\/j.biopha.2026.119912_bib44","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.V90.5.2041","article-title":"RheothRx (Poloxamer 188) Injection for the Acute Painful Episode of Sickle Cell Disease: A Pilot Study","volume":"90","author":"Adams-Graves","year":"1997","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.biopha.2026.119912_bib45","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.nano.2009.05.004","article-title":"The effect of poloxamer 188 on nanoparticle morphology, size, cancer cell uptake, and cytotoxicity","volume":"6","author":"Yan","year":"2010","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"issue":"6","key":"10.1016\/j.biopha.2026.119912_bib46","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1016\/j.actbio.2009.11.035","article-title":"A novel paclitaxel-loaded poly(\u03b5-caprolactone)\/Poloxamer 188 blend nanoparticle overcoming multidrug resistance for cancer treatment","volume":"6","author":"Zhang","year":"2010","journal-title":"Acta Biomater."},{"issue":"6","key":"10.1016\/j.biopha.2026.119912_bib47","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1002\/jps.21581","article-title":"Local delivery of modified paclitaxel-loaded poly(\u03b5-caprolactone)\/pluronic F68 nanoparticles for long-term inhibition of hyperplasia","volume":"98","author":"Mei","year":"2009","journal-title":"J. Pharm. Sci."},{"issue":"24","key":"10.1016\/j.biopha.2026.119912_bib48","doi-asserted-by":"crossref","first-page":"14730","DOI":"10.1021\/acsomega.0c01517","article-title":"Engineering Delivery of Nonbiologics Using Poly(lactic-co-glycolic acid) Nanoparticles for Repair of Disrupted Brain Endothelium","volume":"5","author":"Inyang","year":"2020","journal-title":"ACS Omega"},{"issue":"1","key":"10.1016\/j.biopha.2026.119912_bib49","doi-asserted-by":"crossref","first-page":"19516","DOI":"10.1038\/s41598-024-69888-1","article-title":"Combination chemotherapy via poloxamer 188 surface-modified PLGA nanoparticles that traverse the blood\u2013brain\u2013barrier in a glioblastoma model","volume":"14","author":"Madani","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119912_bib50","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-024-02391-8","article-title":"IL-10R inhibition reprograms tumor-associated macrophages and reverses drug resistance in multiple myeloma","author":"Sun","year":"2024","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.biopha.2026.119912_bib51","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1080\/10428194.2021.1919657","article-title":"3D tissue engineered plasma cultures support leukemic proliferation and induces drug resistance","volume":"62","author":"Alhallak","year":"2021","journal-title":"Leuk. & Lymphoma"},{"issue":"1","key":"10.1016\/j.biopha.2026.119912_bib52","doi-asserted-by":"crossref","DOI":"10.1117\/1.3520571","article-title":"Optical techniques for tracking multiple myeloma engraftment, growth, and response to therapy","volume":"16","author":"Runnels","year":"2011","journal-title":"J. Biomed. Opt."},{"issue":"7347","key":"10.1016\/j.biopha.2026.119912_bib53","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10144","article-title":"Molecular mechanisms and clinical applications of angiogenesis","volume":"473","author":"Carmeliet","year":"2011","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.biopha.2026.119912_bib54","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1158\/1535-7163.MCT-08-0981","article-title":"The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects","volume":"8","author":"Schwartz","year":"2009","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"10.1016\/j.biopha.2026.119912_bib55","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.semradonc.2004.04.005","article-title":"The relationship between hypoxia and angiogenesis","volume":"14","author":"Moeller","year":"2004","journal-title":"Semin. Radiat. Oncol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119912_bib56","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ccell.2014.10.006","article-title":"Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia","volume":"26","author":"Jain","year":"2014","journal-title":"Cancer Cell."},{"issue":"4","key":"10.1016\/j.biopha.2026.119912_bib57","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0061641","article-title":"Poloxamer 188 Protects Neurons against Ischemia\/Reperfusion Injury through Preserving Integrity of Cell Membranes and Blood Brain Barrier","volume":"8","author":"Gu","year":"2013","journal-title":"PLOS ONE"},{"issue":"2","key":"10.1016\/j.biopha.2026.119912_bib58","doi-asserted-by":"crossref","first-page":"C253","DOI":"10.1152\/ajpcell.00321.2019","article-title":"Multiple poloxamers increase plasma membrane repair capacity in muscle and nonmuscle cells","volume":"318","author":"Kwiatkowski","year":"2020","journal-title":"Am. J. Physiol. Cell. Physiol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119912_bib59","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jacbts.2016.04.001","article-title":"Intracoronary Poloxamer 188 Prevents Reperfusion Injury in a Porcine Model of ST-Segment Elevation Myocardial Infarction","volume":"1","author":"Bartos","year":"2016","journal-title":"JACC Basic. Transl. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2026.119912_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40883-017-0044-9","article-title":"Surfactant Copolymer Annealing of Chemically Permeabilized Cell Membranes","volume":"4","author":"Chen","year":"2018","journal-title":"Regen. Eng. Transl. Med."},{"issue":"4","key":"10.1016\/j.biopha.2026.119912_bib61","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.bbamem.2008.11.005","article-title":"Loss of tight junction barrier function and its role in cancer metastasis","volume":"1788","author":"Martin","year":"2009","journal-title":"Biochim. Et. Biophys. Acta (BBA) - Biomembr."},{"issue":"9","key":"10.1016\/j.biopha.2026.119912_bib62","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s00018-019-03351-7","article-title":"Tumor angiogenesis: causes, consequences, challenges and opportunities","volume":"77","author":"Lugano","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"issue":"4","key":"10.1016\/j.biopha.2026.119912_bib63","doi-asserted-by":"crossref","first-page":"747","DOI":"10.2214\/ajr.177.4.1770747","article-title":"Tumor Transport Physiology","volume":"177","author":"Kuszyk","year":"2001","journal-title":"Am. J. Roentgenol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119912_bib64","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrd3455","article-title":"Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases","volume":"10","author":"Carmeliet","year":"2011","journal-title":"Nat. Rev. Drug. Discov."},{"issue":"4","key":"10.1016\/j.biopha.2026.119912_bib65","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41423-020-00565-9","article-title":"Tumor-infiltrating lymphocytes in the immunotherapy era","volume":"18","author":"Paijens","year":"2021","journal-title":"Cell. & Mol. Immunol."},{"issue":"11","key":"10.1016\/j.biopha.2026.119912_bib66","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/ni.3836","article-title":"De novo induction of intratumoral lymphoid structures and vessel normalization enhances immunotherapy in resistant tumors","volume":"18","author":"Johansson-Percival","year":"2017","journal-title":"Nat. Immunol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119912_bib67","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.addr.2010.04.009","article-title":"The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect","volume":"63","author":"Fang","year":"2011","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.biopha.2026.119912_bib68","article-title":"Doxorubicin-induced cardiotoxicity and risk factors","volume":"50","author":"Belger","year":"2024","journal-title":"Int. J. Cardiol. Heart Vasc."},{"issue":"1","key":"10.1016\/j.biopha.2026.119912_bib69","doi-asserted-by":"crossref","first-page":"15170","DOI":"10.1038\/s41598-025-97079-z","article-title":"Cardioprotection by poloxamer 188 is mediated through increased endothelial nitric oxide production","volume":"15","author":"Chen","year":"2025","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.biopha.2026.119912_bib70","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1080\/1120009X.2023.2300217","article-title":"Mechanisms underlying dose-limiting toxicities of conventional chemotherapeutic agents","volume":"36","author":"Manavi","year":"2024","journal-title":"J. Chemother."},{"key":"10.1016\/j.biopha.2026.119912_bib71","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.702726","article-title":"Regulatory T Cells: Barriers of Immune Infiltration Into the Tumor Microenvironment","volume":"12","author":"Scott","year":"2021","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119912_bib72","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006401","article-title":"Barriers to immune cell infiltration in tumors","volume":"11","author":"Melssen","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"11","key":"10.1016\/j.biopha.2026.119912_bib73","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1038\/s12276-023-01114-w","article-title":"Normalization of the tumor microenvironment by harnessing vascular and immune modulation to achieve enhanced cancer therapy","volume":"55","author":"Choi","year":"2023","journal-title":"Exp. & Mol. Med."},{"key":"10.1016\/j.biopha.2026.119912_bib74","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2026.1755928","article-title":"Regulatory T cells in hypoxic environments","volume":"17","author":"Gonz\u00e1lez-Rivera","year":"2026","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119912_bib75","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.molimm.2015.08.004","article-title":"Hypoxia-inducible factors regulate T cell metabolism and function","volume":"68","author":"Phan","year":"2015","journal-title":"Mol. Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119912_bib76","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines6020056","article-title":"Hypoxia, Metabolism and Immune Cell Function","volume":"6","author":"Krzywinska","year":"2018","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.biopha.2026.119912_bib77","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41392-023-01332-8","article-title":"Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions","volume":"8","author":"Chen","year":"2023","journal-title":"Signal. Transduct. Target. Ther."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226009480?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226009480?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:03:00Z","timestamp":1790082180000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226009480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":77,"alternative-id":["S0753332226009480"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119912","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Restoration of tumor vascular integrity by P188 improves chemotherapy and immunotherapy efficacy in triple negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119912","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119912"}}